SEARCH

SEARCH BY CITATION

References

  • Ansell, S.M., Ristow, K.M., Habermann, T.M., Wiseman, G.A. & Witzig, T.E. (2002) Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin’s lymphoma. Journal of Clinical Oncology, 20, 38853890.
  • Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P. & Gisselbrecht, C. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. The New England Journal of Medicine, 346, 235242.
  • Cremonesi, M., Ferrari, M., Chinol, M., Bartolomei, M., Stabin, M.G., Sacco, E., Fiorenza, M., Tosi, G. & Paganelli, G. (2000) Dosimetry in radionuclide therapies with 90Y-conjugates: the IEO experience. Quarterly Journal of Nuclear Medicine, 44, 325332.
  • Devizzi, L., Seregni, E., Guidetti, A., Forni, C., Coliva, A., Magni, M., Di Nicola, M., Carlo-Stella, C., Matteucci, P., De Pascale, A., Erminero, C., Maccauro, M., Chiesa, C., Bombardieri, E. & Gianni, A.M. (2005) High-dose myeloablative zevalin radioimmunotherapy with tandem stem-cell autografting has minimal toxicity and full feasibility in an outpatient setting. Blood (ASH Annual Meeting Abstracts), 106, 2737.
  • Dreyling, M., Lenz, G., Hoster, E., Van Hoof, A., Gisselbrecht, C., Schmits, R., Metzner, B., Truemper, L., Reiser, M., Steinhauer, H., Boiron, J.M., Boogaerts, M.A., Aldaoud, A., Silingardi, V., Kluin-Nelemans, H.C., Hasford, J., Parwaresch, R., Unterhalt, M. & Hiddemann, W. (2005) Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood, 105, 26772684.
  • Foran, J.M., Rohatiner, A.Z., Cunningham, D., Popescu, R.A., Solal-Celigny, P., Ghielmini, M., Coiffier, B., Johnson, P.W., Gisselbrecht, C., Reyes, F., Radford, J.A., Bessell, E.M., Souleau, B., Benzohra, A. & Lister, T.A. (2000) European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. Journal of Clinical Oncology, 18, 317324.
  • Freedman, A.S., Neuberg, D., Mauch, P., Soiffer, R.J., Anderson, K.C., Fisher, D.C., Schlossman, R., Alyea, E.P., Takvorian, T., Jallow, H., Kuhlman, C., Ritz, J., Nadler, L.M. & Gribben, J.G. (1999) Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood, 94, 33253333.
  • Gopal, A.K., Gooley, T.A., Golden, J.B., Maloney, D.G., Bensinger, W.I., Petersdorf, S.H., Appelbaum, F.R. & Press, O.W. (2001) Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin’s lymphoma in adults 60 years of age and older. Bone Marrow Trasplantation, 27, 593599.
  • Gopal, A.K., Rajendran, J.G., Petersdorf, S.H., Maloney, D.G., Eary, J.F., Wood, B.L., Gooley, T.A., Bush, S.A., Durack, L.D., Martin, P.J., Matthews, D.C., Appelbaum, F.R., Bernstein, I.D. & Press, O.W. (2002) High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood, 99, 31583162.
  • Gopal, A.K., Rajendran, J.G., Gooley, T.A., Pagel, J.M., Fisher, D.R., Petersdorf, S., Maloney, D.G., Appelbaum, F.R. & Press, O.W. (2005) A phase II study of myeloablative I-131-anti CD-20 (Tositumomab) radioimmunotherapy and autologous hematopoietic stem cell transplantation (ASCT) for adults ≥60 years of age with high-risk relapsed or refractory B-cell lymphoma. Blood (ASH Annual Meeting Abstracts), 106, 487.
  • Gulati, S., Yahalom, J., Acaba, L., Reich, L., Motzer, R., Crown, J., Toia, M., Igarashi, T., Lemoli, R. & Hanninen, E. (1992) Treatment of patients with relapsed and resistant non-Hodgkin’s lymphoma using total body irradiation, etoposide, and cyclophosphamide and autologous bone marrow transplantation. Journal of Clinical Oncology, 10, 936941.
  • Juweid, M.E. (2002) Radioimmunotherapy of B-cell non-Hodgkin’s lymphoma: from clinical trials to clinical practice. Journal of Nuclear Medicine, 43, 15071529.
  • Juweid, M., Matthies, A. & Schuster, S.L. (2000) Conventional and hematopoietic stem-cell-supported (HSC-supported) radioimmunotherapy of relapsed/refractory non-Hodgkin’s lymphoma (NHL) with 90Y-humanized LL2 (90Y-hLL2) anti-CD22 monoclonal antibody (MAb). Journal of Nuclear Medicine, 41, 31 p., (Suppl.).
  • Krishnan, A., Raubitschek, A., Forman, S.J., Fung, H., Molina, A., Yamauchi, D., Falk, P., Spielberger, R., Popplewell, L., Rodriguez, R., Parker, P., Chow, W., Nakamura, R. & Nademanee, A. (2005) New transplant strategies utilizing radioimmunotherapy (RIT) based regimens to reduce relapse in high risk mantle cell lymphoma (MCL). Blood (ASH Annual Meeting Abstracts), 106, 681.
  • Liu, S.Y., Eary, J.F., Petersdorf, S.H., Martin, P.J., Maloney, D.G., Appelbaum, F.R., Matthews, D.C., Bush, S.A., Durack, L.D., Fisher, D.R., Gooley, T.A., Bernstein, I.D. & Press, O.W. (1998) Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. Journal of Clinical Oncology, 16, 32703278.
  • Maloney, D.G., Liles, T.M., Czerwinski, D.K., Waldichuk, C., Rosenberg, J., Grillo-Lopez, A. & Levy, R. (1994) Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood, 84, 24572466.
  • Maloney, D.G., Grillo-López, A.J., Bodkin, D.J., White, C.A., Liles, T.M., Royston, I., Varns, C., Rosenberg, J. & Levy, R. (1997a) IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin’s lymphoma. Journal of Clinical Oncology, 15, 32663274.
  • Maloney, D.G., Grillo-López, A.J., White, C.A., Bodkin, D., Schilder, R.J., Neidhart, J.A., Janakiraman, N., Foon, K.A., Liles, T.M., Dallaire, B.K., Wey, K., Royston, I., Davis, T. & Levy, R. (1997b) IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood, 90, 21882195.
  • McLaughlin, P., Grillo-López, A.J., Link, B.K., Levy, R., Czuczman, M.S., Williams, M.E., Heyman, M.R., Bence-Bruckler, I., White, C.A., Cabanillas, F., Jain, V., Ho, A.D., Lister, J., Wey, K., Shen, D. & Dallaire, B.K. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Journal of Clinical Oncology, 16, 28252833.
  • Morschhauser, F., Illidge, T., Huglo, D., Martinelli, G., Paganelli, G., Zinzani, P.L., Rule, S., Liberati, A.M., Milpied, N., Hess, G., Stein, H., Kalmus, J. & Marcus, R. (2007) Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood, 110, 5458.
  • Nademanee, A., Molina, A., Dagis, A., Snyder, D.S., O’Donnell, M.R., Parker, P., Stein, A., Smith, E., Planas, I., Kashyap, A., Spielberger, R., Fung, H., Krishnan, A., Bhatia, R., Wong, K.K., Somlo, G., Margolin, K., Chow, W., Sniecinski, I., Vora, N., Slovak, M., Niland, J.C. & Forman, S.J. (2000) Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin’s lymphoma. Clinical Lymphoma, 1, 4654.
  • Nademanee, A., Forman, S., Molina, A., Fung, H., Smith, D., Dagis, A., Kwok, C., Yamauchi, D., Anderson, A.L., Falk, P., Krishnan, A., Kirschbaum, M., Kogut, N., Nakamura, R., O’donnell, M., Parker, P., Popplewell, L., Pullarkat, V., Rodriguez, R., Sahebi, F., Smith, E., Snyder, D., Stein, A., Spielberger, R., Zain, J., White, C. & Raubitschek, A. (2005) A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood, 106, 28962902.
  • Paganelli, G., Bartolomei, M., Grana, C., Ferrari, M., Rocca, P. & Chinol, M. (2006) Radioimmunotherapy of brain tumor. Neurology Research, 28, 518522.
  • Philip, T., Guglielmi, C., Hagenbeek, A., Somers, R., Van der Lelie, H., Bron, D., Sonneveld, P., Gisselbrecht, C., Cahn, J.Y. & Harousseau, J.L. (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. The New England Journal of Medicine, 333, 15401545.
  • Press, O.W., Eary, J.F., Appelbaum, F.R., Martin, P.J., Badger, C.C., Nelp, W.B., Glenn, S., Butchko, G., Fisher, D. & Porter, B. (1993) Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. The New England Journal of Medicine, 329, 12191224.
  • Press, O.W., Eary, J.F., Appelbaum, F.R., Martin, P.J., Nelp, W.B., Glenn, S., Fisher, D.R., Porter, B., Matthews, D.C. & Gooley, T. (1995) Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet, 346, 336340.
  • Shen, S., Forero, A., LoBuglio, A.F., Breitz, H., Khazaeli, M.B., Fisher, D.R., Wang, W. & Meredith, R.F. (2005) Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies. Journal of Nuclear Medicine, 46, 642651.
  • Shimoni, A., Zwas, T., Oksman, Y., Hardan, I., Shem-Tov, N., Yerushalmi, R., Avigdor, A., Ben-Bassat, I. & Nagler, A. (2005) Ibritumomab tiuxetan (zevalin) in the conditioning regimen for autologous and reduced-intensity allogeneic stem-cell transplantation in patients with chemo-refractory non-Hodgkin’s lymphoma. Blood (ASH Annual Meeting Abstracts), 106, 1131.
  • Shipp, M.A., Abeloff, M.D., Antman, K.H., Carroll, G., Hagenbeek, A., Loeffler, M., Montserrat, E., Radford, J.A., Salles, G., Schmitz, N., Symann, M., Armitage, J.O., Philip, T. & Coiffier, B. (1999) International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin’s Lymphomas: report of the jury. Journal of Clinical Oncology, 17, 423429.
  • Vose, J.M., Anderson, J.R., Kessinger, A., Bierman, P.J., Coccia, P., Reed, E.C., Gordon, B. & Armitage, J.O. (1993) High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin’s lymphoma. Journal of Clinical Oncology, 11, 18461851.
  • Vose, J.M., Link, B.K., Grossbard, M.L., Czuczman, M., Grillo-Lopez, A., Gilman, P., Lowe, A., Kunkel, L.A. & Fisher, R.I. (2001) Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin’s lymphoma. Journal of Clinical Oncology, 19, 389397.
  • Winter, J.N. (2004) Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin’s lymphoma. Clinical Lymphoma, 5(Suppl. 1), S22S26.
  • Winter, J.N., Inwards, D. & Erwin, W. (2001) Phase I trial combining 90Y zevalin and high-dose BEAM chemotherapy with hematopoietic progenitor cell transplant in relapsed or refractory B-cell NHL. Blood, 98, 677a678a, (abstract).
  • Winter, J.N., Inwards, D.J. & Spies, S. (2004) 90Y Ibritumomab Tiuxetan (Zevalin®; 90YZ) doses higher than 4 mCi/kg may be safely combined with high-dose beam and autotransplant: the role for dosimetry. Blood, 104, 1162, (abstract).
  • Wiseman, G.A., Kornmehl, E., Leigh, B., Erwin, W.D., Podoloff, D.A., Spies, S., Sparks, R.B., Stabin, M.G., Witzig, T. & White, C.A. (2003) Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin’s lymphoma: combined data from 4 clinical trials. Journal of Nuclear Medicine, 44, 465474.
  • Witzig, T.E., White, C.A., Wiseman, G.A., Gordon, L.I., Emmanouilides, C., Raubitschek, A., Janakiraman, N., Gutheil, J., Schilder, R.J., Spies, S., Silverman, D.H., Parker, E. & Grillo-López, A.J. (1999) Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin’s lymphoma. Journal of Clinical Oncology, 17, 37933803.
  • Witzig, T.E., Gordon, L.I., Cabanillas, F., Czuczman, M.S., Emmanouilides, C., Joyce, R., Pohlman, B.L., Bartlett, N.L., Wiseman, G.A., Padre, N., Grillo-López, A.J., Multani, P. & White, C.A. (2002a) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. Journal of Clinical Oncology, 20, 24532463.
  • Witzig, T.E., Flinn, I.W., Gordon, L.I., Emmanouilides, C., Czuczman, M.S., Saleh, M.N., Cripe, L., Wiseman, G., Olejnik, T., Multani, P.S. & White, C.A. (2002b) Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma. Journal of Clinical Oncology, 20, 32623269.